VDJ002 is a potential third-generation CTLA-4-Fc fusion protein drug that can simultaneously bind with high affinity to both CD80 and CD86

VDJ002 is a potential third-generation CTLA-4-Fc fusion protein drug that can simultaneously bind with high affinity to both CD80 and CD86, thereby inhibiting CD28-mediated T-cell activation and exerting an immunosuppressive effect. The affinity of VDJ002 for CD80 and CD86 is approximately 30 times and 250 times higher than that of Bristol Myers Squibb's abatacept, respectively, and about 5 times and 25 times higher than that of belatacept. It is expected to become a best-in-class drug for inhibiting T-cell activation. This candidate has completed Phase I clinical trials.